LIPID MAPS uses cookies to keep the site working, to remember your choices, and — only if you allow it — to understand how the site is used so we can improve it. Choose what you are happy with below. You can change your mind at any time from Manage Cookies in the footer.
Register to help us understand how LIPID MAPS resources are used, measure our impact and improve our services.
Compactin is a potent competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis. Experiments were conducted with peritoneal macrophages, obtained from thioglycolate-stimulated mice, as per protocols PP0000001401, PP0000001502 and PP0000001801.
For the 8 time point study, cells were treated for 0, 0.5, 1, 2, 4, 8, 12, or 24 hours with Kdo2-Lipid A. Untreated cells were used as a zero timepoint. Three separate experiments (biological replicates) were carried out, and a single MS measurement was performed on each sample. Measurements were taken at each timepoint for: (i) Kdo2-Lipid A + compactin, (ii) Kdo2-Lipid A, (iii) compactin, and (iv) control.
Kdo2-Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4. Raetz C, Garrett T, Reynolds C, Shaw W, Moore J, Smith JD, Ribeiro A, Murphy R, Ulevitch R, Fearns C, Reichart D, Glass C, Benner C, Subramaniam S, Harkewicz R, Bowers-Gentry R, Buczynski M, Cooper J, Deems R and Dennis E. Journal of Lipid Research 47, 1097-1111 (2006) PMID:16479018 [doi:10.1194/jlr.M600027-JLR200]
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties.